JATT Acquisition (JATT) Competitors $1.13 +0.01 (+0.89%) As of 07/3/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock JATT vs. ANEB, PLRX, ZURA, ONCY, GNTA, QNCX, INCR, ABOS, PYXS, and IMUXShould you be buying JATT Acquisition stock or one of its competitors? The main competitors of JATT Acquisition include Anebulo Pharmaceuticals (ANEB), Pliant Therapeutics (PLRX), Zura Bio (ZURA), Oncolytics Biotech (ONCY), Genenta Science (GNTA), Quince Therapeutics (QNCX), InterCure (INCR), Acumen Pharmaceuticals (ABOS), Pyxis Oncology (PYXS), and Immunic (IMUX). These companies are all part of the "pharmaceutical products" industry. JATT Acquisition vs. Its Competitors Anebulo Pharmaceuticals Pliant Therapeutics Zura Bio Oncolytics Biotech Genenta Science Quince Therapeutics InterCure Acumen Pharmaceuticals Pyxis Oncology Immunic JATT Acquisition (NYSE:JATT) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings. Is JATT or ANEB more profitable? JATT Acquisition's return on equity of -49.58% beat Anebulo Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets JATT AcquisitionN/A -49.58% 2.84% Anebulo Pharmaceuticals N/A -90.11%-84.53% Which has stronger earnings & valuation, JATT or ANEB? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJATT AcquisitionN/AN/A$6.85MN/AN/AAnebulo PharmaceuticalsN/AN/A-$8.20M-$0.26-6.33 Do analysts prefer JATT or ANEB? Anebulo Pharmaceuticals has a consensus price target of $5.50, indicating a potential upside of 234.35%. Given Anebulo Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Anebulo Pharmaceuticals is more favorable than JATT Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score JATT Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Anebulo Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders have more ownership in JATT or ANEB? 48.0% of JATT Acquisition shares are held by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. 20.0% of JATT Acquisition shares are held by insiders. Comparatively, 80.6% of Anebulo Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media favor JATT or ANEB? In the previous week, JATT Acquisition's average media sentiment score of 0.00 equaled Anebulo Pharmaceuticals'average media sentiment score. Company Overall Sentiment JATT Acquisition Neutral Anebulo Pharmaceuticals Neutral SummaryJATT Acquisition and Anebulo Pharmaceuticals tied by winning 4 of the 8 factors compared between the two stocks. Get JATT Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for JATT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding JATT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JATT vs. The Competition Export to ExcelMetricJATT AcquisitionBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$19.49M$205.72M$5.53B$20.71BDividend YieldN/AN/A5.24%3.72%P/E RatioN/AN/A19.3125.95Price / SalesN/A242.79424.5938.53Price / Cash27.0822.4426.2118.22Price / Book-2.135.557.924.59Net Income$6.85M-$96.61M$3.17B$982.91M7 Day Performance7.62%-1.69%2.18%1.73%1 Month Performance-10.32%-2.54%1.25%4.26%1 Year Performance-67.71%11.05%33.90%14.35% JATT Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JATTJATT AcquisitionN/A$1.13+0.9%N/A-67.7%$19.49MN/A0.003Gap UpHigh Trading VolumeANEBAnebulo Pharmaceuticals2.1916 of 5 stars$1.81+3.4%$5.50+203.9%-34.2%$71.90MN/A-6.964High Trading VolumePLRXPliant Therapeutics3.9483 of 5 stars$1.20+2.6%$13.31+1,009.4%-88.2%$71.82M$1.58M-0.3390Gap UpZURAZura Bio3.4826 of 5 stars$1.12+6.7%$14.33+1,179.8%-67.5%$71.79MN/A-1.603Positive NewsGap UpONCYOncolytics Biotech1.6628 of 5 stars$0.79+5.0%$4.33+450.3%-12.5%$70.71MN/A-2.7230Gap DownHigh Trading VolumeGNTAGenenta Science1.8478 of 5 stars$3.87+1.3%$25.00+546.0%+25.1%$69.87MN/A0.007Gap UpQNCXQuince Therapeutics2.8764 of 5 stars$1.60+5.3%$8.00+400.0%+120.1%$69.11MN/A-1.1560INCRInterCureN/A$1.48flatN/A-35.4%$67.45M$64.55M0.00350ABOSAcumen Pharmaceuticals1.2378 of 5 stars$1.13+1.8%$6.33+460.5%-49.6%$67.24MN/A-0.5820Positive NewsPYXSPyxis Oncology1.2081 of 5 stars$1.20+11.1%$9.00+650.0%-61.6%$66.90M$16.15M-0.7560IMUXImmunic2.9282 of 5 stars$0.71+3.3%$11.60+1,526.9%-32.5%$66.15MN/A-0.5870Positive News Related Companies and Tools Related Companies ANEB Alternatives PLRX Alternatives ZURA Alternatives ONCY Alternatives GNTA Alternatives QNCX Alternatives INCR Alternatives ABOS Alternatives PYXS Alternatives IMUX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:JATT) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding JATT Acquisition Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share JATT Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
